{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:27:20Z","timestamp":1769088440339,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejso.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T16:03:36Z","timestamp":1618848216000},"page":"2533-2542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1\/2 expression in hepatocellular carcinoma beyond the Milan Criteria"],"prefix":"10.1016","volume":"47","author":[{"given":"Qianwei","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunbin","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangjiang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaonan","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejso.2021.04.001_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J Clin"},{"issue":"10204","key":"10.1016\/j.ejso.2021.04.001_bib2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","article-title":"Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"394","author":"Zhou","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejso.2021.04.001_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.ejso.2021.04.001_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejso.2021.04.001_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-2005-871198","article-title":"Resection and liver transplantation for hepatocellular carcinoma","volume":"25","author":"Llovet","year":"2005","journal-title":"Semin Liver Dis"},{"issue":"11","key":"10.1016\/j.ejso.2021.04.001_bib6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2021.04.001_bib7","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/hep.27288","article-title":"Earlier presentation and application of curative treatments in hepatocellular carcinoma","volume":"60","author":"Ulahannan","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ejso.2021.04.001_bib8","article-title":"Hangzhou criteria as downstaging criteria in hepatocellular carcinoma before liver transplantation: a multicenter study from China","author":"Zhan","year":"2020","journal-title":"HBPD INT"},{"issue":"6","key":"10.1016\/j.ejso.2021.04.001_bib9","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.ejso.2021.04.001_bib10","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/lt.21281","article-title":"Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation","volume":"13","author":"Ito","year":"2007","journal-title":"Liver Transplant : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society"},{"issue":"1","key":"10.1016\/j.ejso.2021.04.001_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2021.04.001_bib12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gutjnl-2014-308513","article-title":"Liver transplantation for hepatocellular carcinoma beyond the Milan criteria","volume":"65","author":"Xu","year":"2016","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.ejso.2021.04.001_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL clinical practice guidelines: liver transplantation","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.ejso.2021.04.001_bib14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/gut.2008.163527","article-title":"Immunosuppression for liver transplantation","volume":"58","author":"Geissler","year":"2009","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.ejso.2021.04.001_bib15","first-page":"376","article-title":"Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation","volume":"6","author":"Yang","year":"2007","journal-title":"HBPD INT"},{"issue":"5","key":"10.1016\/j.ejso.2021.04.001_bib16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/lt.24395","article-title":"Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma","volume":"22","author":"Yanik","year":"2016","journal-title":"Liver Transplant"},{"issue":"9","key":"10.1016\/j.ejso.2021.04.001_bib17","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/01.tp.0000262607.95372.e0","article-title":"De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects","volume":"83","author":"Toso","year":"2007","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.ejso.2021.04.001_bib18","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","article-title":"Pivotal role of mTOR signaling in hepatocellular carcinoma","volume":"135","author":"Villanueva","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ejso.2021.04.001_bib19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.ejso.2021.04.001_bib20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4254\/wjh.v6.i11.776","article-title":"Mammalian target of rapamycin inhibition in hepatocellular carcinoma","volume":"6","author":"Ashworth","year":"2014","journal-title":"World J Hepatol"},{"issue":"8","key":"10.1016\/j.ejso.2021.04.001_bib21","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/gutjnl-2016-312734","article-title":"TSC1\/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication","volume":"66","author":"Ho","year":"2017","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.ejso.2021.04.001_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.21037\/atm.2020.01.10","article-title":"Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria","volume":"8","author":"Ling","year":"2020","journal-title":"Ann Transl Med"},{"issue":"7","key":"10.1016\/j.ejso.2021.04.001_bib23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","article-title":"Tissue microarrays for high-throughput molecular profiling of tumor specimens","volume":"4","author":"Kononen","year":"1998","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ejso.2021.04.001_bib24","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/gutjnl-2019-319616","article-title":"USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1alpha\/USP22 positive feedback loop upon TP53 inactivation","volume":"69","author":"Ling","year":"2020","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.ejso.2021.04.001_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/lt.21420","article-title":"Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"14","author":"Zimmerman","year":"2008","journal-title":"Liver Transplant"},{"issue":"12","key":"10.1016\/j.ejso.2021.04.001_bib26","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/lt.21953","article-title":"Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation","volume":"15","author":"Chinnakotla","year":"2009","journal-title":"Liver Transplant"},{"issue":"2","key":"10.1016\/j.ejso.2021.04.001_bib27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/TP.0b013e3181c3c540","article-title":"Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma","volume":"89","author":"Vivarelli","year":"2010","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ejso.2021.04.001_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/lt.22441","article-title":"Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis","volume":"18","author":"Liang","year":"2012","journal-title":"Liver Transplant"},{"issue":"4","key":"10.1016\/j.ejso.2021.04.001_bib29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/apt.12185","article-title":"Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma","volume":"37","author":"Menon","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ejso.2021.04.001_bib30","first-page":"1260","article-title":"Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"49","author":"Grigg","year":"2019"},{"issue":"7","key":"10.1016\/j.ejso.2021.04.001_bib31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1080\/08941939.2018.1447053","article-title":"Sirolimus in liver transplant recipients with hepatocellular carcinoma: an updated meta-analysis","volume":"32","author":"Zhang","year":"2019","journal-title":"J\u00a0Invest Surg : the official journal of the Academy of Surgical Research"},{"issue":"4","key":"10.1016\/j.ejso.2021.04.001_bib32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.23437","article-title":"Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma","volume":"51","author":"Toso","year":"2010","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.ejso.2021.04.001_bib33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lt.23479","article-title":"Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database","volume":"18","author":"Watt","year":"2012","journal-title":"Liver Transplant"},{"issue":"10","key":"10.1016\/j.ejso.2021.04.001_bib34","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/lt.20237","article-title":"Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma","volume":"10","author":"Kneteman","year":"2004","journal-title":"Liver Transplant : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society"},{"issue":"10","key":"10.1016\/j.ejso.2021.04.001_bib35","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.transproceed.2008.03.165","article-title":"Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria","volume":"40","author":"Zhou","year":"2008","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.ejso.2021.04.001_bib36","first-page":"4407","article-title":"Novel strategy of sirolimus plus thymalfasin and huaier granule on tumor recurrence of hepatocellular carcinoma beyond the UCSF criteria following liver transplantation: a single center experience","volume":"16","author":"Zhou","year":"2018","journal-title":"Oncology letters"},{"issue":"1","key":"10.1016\/j.ejso.2021.04.001_bib37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.ejso.2021.04.001_bib38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","article-title":"mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors","volume":"272","author":"Schnitzbauer","year":"2020","journal-title":"Ann Surg"},{"issue":"217","key":"10.1016\/j.ejso.2021.04.001_bib39","doi-asserted-by":"crossref","first-page":"ra24","DOI":"10.1126\/scisignal.2002739","article-title":"Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice","volume":"5","author":"Menon","year":"2012","journal-title":"Sci Signal"},{"issue":"5","key":"10.1016\/j.ejso.2021.04.001_bib40","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/SLA.0b013e3181896278","article-title":"Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence","volume":"248","author":"Vivarelli","year":"2008","journal-title":"Ann Surg"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321004078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321004078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:39:04Z","timestamp":1760060344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798321004078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0748798321004078"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2021.04.001","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1\/2 expression in hepatocellular carcinoma beyond the Milan Criteria","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}